Interactions between methylating and pyridyloxobutylating agents in A/J mouse lungs: Implications for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis

Citation
La. Peterson et al., Interactions between methylating and pyridyloxobutylating agents in A/J mouse lungs: Implications for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis, CANCER RES, 61(15), 2001, pp. 5757-5763
Citations number
33
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER RESEARCH
ISSN journal
00085472 → ACNP
Volume
61
Issue
15
Year of publication
2001
Pages
5757 - 5763
Database
ISI
SICI code
0008-5472(20010801)61:15<5757:IBMAPA>2.0.ZU;2-O
Abstract
The tobacco-specific nitrosamine, 4-(methylnitrosoamino)-1-(3-pyridyl)-1-bu tanone, is activated to lung DNA methylating and pyridyloxobutylating inter mediates. It is likely that both pathways play a role in lung tumor initiat ion by this nitrosamine. Previous studies indicated that O-6-methylguanine (O-6-mG) persistence is critical for lung tumor formation in A/J mice. The model pyridyloxobutylating agent, 4-(acetoxymethylnitrosamino)-1-(3-pyridyl )-1-butanone (NNKOAc), enhanced the tumorigenic activity of a model methyla ting agent, acetoxymethylmethylnitrosamine (AMMN), presumably by increasing O-6-mG persistence in lung DNA. We have been testing the hypothesis that t he pyridyloxobutylation pathway increases the mutagenic activity of the DNA methylation pathway by preventing the repair of O-6-mG by O-6-alkylguanine -DNA alkyltransferase (AGT). In this study, we report that NNKOAc depletes AGT in lungs but not livers of A/J mice. The consequences of AGT depletion by NNKOAc were then compared with those observed with a known AGT inhibitor , O-6-benzylguanine (O-6-bG). NNKOAc and O-6-bG had similar effects on the levels of AMMN-derived O-6-mG at 4 and 96 h postinjection. This increase in O-6-mG levels correlated to increased lung tumor multiplicity in animals s imultaneously treated with AMMN (0.75 or 1 mu mol) and NNKOAc or O-6-bG. On ly NNKOAc significantly increased lung tumor multiplicity at doses of 0.25 or 0.5 mu mol AMMN. The results from these studies indicate that the pyridy loxobutylating agent, NNKOAc, can influence the tumorigenic activity of met hylating agents in two ways. At low AMMN doses, the increase in tumor multi plicity is dominated by the additive tumorigenic properties of AMMN and NNK OAc. At higher AMMN doses, NNKOAc appears to enhance the tumorigenic activi ty of AMMN through enhanced depletion of the repair protein, AGT, leading t o increased O-6-mG persistence. It is likely that similar interactions are important for the organospecific effects of 4-(methylnitrosoamino)-1-(3-pyr idyl)-1-butanone.